Cellevate

Executive Summary

Cellevate AB is a Swedish biotech company revolutionizing upstream bioprocessing with its proprietary Cellevat3d® nanofiber-based microcarrier platform. The technology addresses critical bottlenecks in viral vector and vaccine manufacturing by significantly increasing cell culture yields while reducing cost and complexity. Cellevate's solution is particularly relevant for the rapidly expanding cell and gene therapy market, where efficient and scalable production remains a major challenge. Founded in 2015 and headquartered in Lund, the company has positioned itself as an enabler of next-generation biologics manufacturing.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-10 pharma or CDMO for Cellevat3d licensing40% success
• Q2 2027Completion of scale-up validation study for AAV or lentiviral vector production65% success
• Q2 2026Series A funding round or non-dilutive grant award to support commercial expansion55% success